$GNPX
Genprex Inc

2020 Q3 Form 10-Q Financial Statement

#000143774920023671 Filed on November 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q3 2019 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.420M $1.910M $3.200M
YoY Change -25.65% 11.7% -45.95%
% of Gross Profit
Research & Development $1.350M $467.3K $502.0K
YoY Change 188.87% -4.56% 344.41%
% of Gross Profit
Depreciation & Amortization $5.714K $3.437K $3.118K
YoY Change 66.25% 100.64% 166.27%
% of Gross Profit
Operating Expenses $1.350M $467.3K $502.0K
YoY Change 188.87% -4.56% 344.41%
Operating Profit -$2.778M -$2.381M -$3.704M
YoY Change 16.67% 8.35% -38.64%
Interest Expense $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.770M -$2.380M -$3.700M
YoY Change 16.39% 8.68% -38.94%
Income Tax
% Of Pretax Income
Net Earnings -$2.775M -$2.376M -$3.695M
YoY Change 16.8% 8.67% -39.03%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$70.92K -$150.3K -$236.9K
COMMON SHARES
Basic Shares Outstanding 38.87M 15.84M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.06M $2.550M $4.500M
YoY Change 725.88% -75.27% -62.5%
Cash & Equivalents $21.06M $2.548M $4.497M
Short-Term Investments
Other Short-Term Assets $970.0K $260.0K $450.0K
YoY Change 273.08% -29.73% -16.67%
Inventory $690.0K $800.0K $850.0K
Prepaid Expenses
Receivables $0.00 $0.00 $10.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $22.71M $3.609M $5.802M
YoY Change 529.3% -66.24% -53.73%
LONG-TERM ASSETS
Property, Plant & Equipment $42.34K $23.75K $24.37K
YoY Change 78.3% 48.51% 143.65%
Goodwill
YoY Change
Intangibles $587.7K $423.9K $421.5K
YoY Change 38.64% 30.43%
Long-Term Investments
YoY Change
Other Assets $598.5K $435.7K $437.6K
YoY Change 37.37% 2078.28% 30.03%
Total Long-Term Assets $640.8K $459.4K $462.0K
YoY Change 39.48% 27.35% 31.65%
TOTAL ASSETS
Total Short-Term Assets $22.71M $3.609M $5.802M
Total Long-Term Assets $640.8K $459.4K $462.0K
Total Assets $23.35M $4.068M $6.264M
YoY Change 473.99% -63.18% -51.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $320.0K $480.0K $880.0K
YoY Change -33.33% -15.79% 193.33%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $60.00K $60.00K
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $375.7K $537.2K $938.8K
YoY Change -30.08% -5.75% 212.36%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $375.7K $537.2K $938.8K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $380.0K $540.0K $940.0K
YoY Change -29.63% -5.26% 213.33%
SHAREHOLDERS EQUITY
Retained Earnings -$53.19M -$38.05M -$35.68M
YoY Change 39.78% 47.39%
Common Stock $39.46K $15.84K $15.80K
YoY Change 149.09% 13.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $22.98M $3.531M $5.325M
YoY Change
Total Liabilities & Shareholders Equity $23.35M $4.068M $6.264M
YoY Change 473.99% -63.18% -51.41%

Cashflow Statement

Concept 2020 Q3 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income -$2.775M -$2.376M -$3.695M
YoY Change 16.8% 8.67% -39.03%
Depreciation, Depletion And Amortization $5.714K $3.437K $3.118K
YoY Change 66.25% 100.64% 166.27%
Cash From Operating Activities -$2.010M -$1.990M -$1.570M
YoY Change 1.01% 35.37% -49.52%
INVESTING ACTIVITIES
Capital Expenditures -$50.00K $0.00 -$40.00K
YoY Change -100.0% 100.0%
Acquisitions
YoY Change
Other Investing Activities $210.0K $50.00K -$850.0K
YoY Change 320.0%
Cash From Investing Activities $150.0K $40.00K -$890.0K
YoY Change 275.0% -500.0% 4350.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 790.0K 0.000 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -2.010M -1.990M -1.570M
Cash From Investing Activities 150.0K 40.00K -890.0K
Cash From Financing Activities 790.0K 0.000 0.000
Net Change In Cash -1.070M -1.950M -2.460M
YoY Change -45.13% 14.71% -120.53%
FREE CASH FLOW
Cash From Operating Activities -$2.010M -$1.990M -$1.570M
Capital Expenditures -$50.00K $0.00 -$40.00K
Free Cash Flow -$1.960M -$1.990M -$1.530M
YoY Change -1.51% 36.3% -50.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Revenues
Revenues
CY2018Q1 gnpx Capital Stock Shares Authorized
CapitalStockSharesAuthorized
210000000
CY2019 gnpx Class Of Warrant Or Right Cancelled During Period
ClassOfWarrantOrRightCancelledDuringPeriod
gnpx Class Of Warrant Or Right Cancelled During Period
ClassOfWarrantOrRightCancelledDuringPeriod
-24158
CY2019 gnpx Class Of Warrant Or Right Cancelled During Period Exercise Price
ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice
gnpx Class Of Warrant Or Right Cancelled During Period Exercise Price
ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice
0.50
CY2020Q3 gnpx Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
2124747
CY2020Q3 gnpx Class Of Warrant Or Right Exercisable Exercise Price
ClassOfWarrantOrRightExercisableExercisePrice
4.18
CY2019 gnpx Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
gnpx Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
-5627151
CY2019 gnpx Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
gnpx Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
0.46
CY2019 gnpx Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
0.46
gnpx Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
2.41
CY2019 gnpx Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
3611504
gnpx Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
550000
CY2020Q3 gnpx Investment Unit
InvestmentUnit
CY2019Q4 gnpx Investment Unit
InvestmentUnit
CY2019Q1 gnpx Issuance Of Stock For Cash Equity Impact
IssuanceOfStockForCashEquityImpact
CY2019Q2 gnpx Issuance Of Stock For Cash Equity Impact
IssuanceOfStockForCashEquityImpact
CY2019Q3 gnpx Issuance Of Stock For Cash Equity Impact
IssuanceOfStockForCashEquityImpact
40935
CY2020Q1 gnpx Issuance Of Stock For Cash Equity Impact
IssuanceOfStockForCashEquityImpact
25731640
CY2020Q2 gnpx Issuance Of Stock For Cash Equity Impact
IssuanceOfStockForCashEquityImpact
2569342
CY2020Q3 gnpx Issuance Of Stock For Cash Equity Impact
IssuanceOfStockForCashEquityImpact
793531
CY2018Q2 gnpx Nonvoting To Voting Common Stock Conversion Ratio
NonvotingToVotingCommonStockConversionRatio
1
CY2020Q2 gnpx Operating Lease Rent Expense Per Month
OperatingLeaseRentExpensePerMonth
462
gnpx Payments For Proceeds From Research And Development Supplies
PaymentsForProceedsFromResearchAndDevelopmentSupplies
-115456
gnpx Payments For Proceeds From Research And Development Supplies
PaymentsForProceedsFromResearchAndDevelopmentSupplies
801780
CY2010 gnpx Proceeds From State Of Texas Emerging Technology Fund Award
ProceedsFromStateOfTexasEmergingTechnologyFundAward
2250000
CY2011 gnpx Proceeds From State Of Texas Emerging Technology Fund Award
ProceedsFromStateOfTexasEmergingTechnologyFundAward
2250000
CY2020Q3 gnpx Research And Development Assets Current
ResearchAndDevelopmentAssetsCurrent
686324
CY2019Q4 gnpx Research And Development Assets Current
ResearchAndDevelopmentAssetsCurrent
801780
CY2010Q4 gnpx State Of Texas Emerging Technology Fund Award Amount
StateOfTexasEmergingTechnologyFundAwardAmount
4500000
gnpx Stock Cancelled During Period Shares
StockCancelledDuringPeriodShares
24158
gnpx Stock Issued During Period Shares Warrants Issued
StockIssuedDuringPeriodSharesWarrantsIssued
5511599
CY2020Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
321424
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
436258
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
76130492
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
43483740
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
330626
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1615896
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
540808
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
752444
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2359621
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
432590
CY2020Q3 us-gaap Assets
Assets
23351696
CY2019Q4 us-gaap Assets
Assets
3534229
CY2020Q3 us-gaap Assets Current
AssetsCurrent
22710903
CY2019Q4 us-gaap Assets Current
AssetsCurrent
2976643
CY2020Q3 us-gaap Cash
Cash
21058386
CY2019Q4 us-gaap Cash
Cash
2002492
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2002492
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8600918
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21058386
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2548433
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
19055894
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6052485
CY2020Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2020Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
20811895
CY2019Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1761278
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.36
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.45
CY2020Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.01
CY2020Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
115552
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3864552
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7476056
CY2020Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2374747
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39463722
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19263841
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39463722
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19263841
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
39464
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
19264
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
2777593
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
2380763
us-gaap Costs And Expenses
CostsAndExpenses
12731923
us-gaap Costs And Expenses
CostsAndExpenses
8255419
CY2020Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
10741
CY2019Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
21732
us-gaap Depreciation
Depreciation
16843
us-gaap Depreciation
Depreciation
9486
CY2020Q3 us-gaap Depreciation
Depreciation
5714
CY2019Q3 us-gaap Depreciation
Depreciation
3437
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2013Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2500000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1421863
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1909982
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7731550
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6768506
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Income Taxes Paid
IncomeTaxesPaid
us-gaap Income Taxes Paid
IncomeTaxesPaid
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-114834
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
189907
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-570
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-9297
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-10991
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-6353
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-20195
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-34497
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
794392
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
27862
CY2020Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
587712
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
491200
us-gaap Interest Paid Net
InterestPaidNet
us-gaap Interest Paid Net
InterestPaidNet
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2650
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
5051
us-gaap Investment Income Interest
InvestmentIncomeInterest
17467
us-gaap Investment Income Interest
InvestmentIncomeInterest
25620
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23351696
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3534229
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
375655
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
510684
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29094513
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4415
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-855132
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10043034
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5197353
us-gaap Net Income Loss
NetIncomeLoss
-12714456
us-gaap Net Income Loss
NetIncomeLoss
-8229799
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-2158846
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-3695240
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-2375712
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-5566220
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4373293
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2774943
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2777593
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2380763
us-gaap Operating Income Loss
OperatingIncomeLoss
-12731923
us-gaap Operating Income Loss
OperatingIncomeLoss
-8255419
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
598453
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
512932
CY2020Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
54231
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
74426
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
96512
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
44473
CY2019Q3 us-gaap Revenues
Revenues
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14529
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8879
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
966108
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
171716
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
29094513
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2537731
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
42340
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
44654
CY2020Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
85
CY2019Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
655
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1350016
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
467344
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4983530
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1477427
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-53193915
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-40479459
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
15000
CY2019 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
506707
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5511599
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
976730
us-gaap Revenues
Revenues
us-gaap Revenues
Revenues
us-gaap Share Based Compensation
ShareBasedCompensation
3572439
us-gaap Share Based Compensation
ShareBasedCompensation
2879762
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4857491
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
297058
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
164837
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
164837
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
297058
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
9.80
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2141529
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1744300
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6982885
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4535681
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5982923
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.31
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.66
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.78
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
218260
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.70
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.84
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.48
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.78
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y266D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y164D
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
27900
CY2019 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
469588
CY2019Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
192396
CY2019Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
159101
CY2020Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1550
CY2020Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
10884
CY2020Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
15350
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2537731
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
825027
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
8881135
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
7245311
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
5325068
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
3531099
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
3023545
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
23942959
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
24509513
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
22976041
CY2018Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
6.6841954
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The preparation of our condensed financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div></div></div>
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39055159
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15831822
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34139991
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15598644

Files In Submission

Name View Source Status
0001437749-20-023671-index-headers.html Edgar Link pending
0001437749-20-023671-index.html Edgar Link pending
0001437749-20-023671.txt Edgar Link pending
0001437749-20-023671-xbrl.zip Edgar Link pending
ex_200522.htm Edgar Link pending
ex_200523.htm Edgar Link pending
ex_200524.htm Edgar Link pending
ex_213674.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gnpx-20200930.xml Edgar Link completed
gnpx-20200930.xsd Edgar Link pending
gnpx-20200930_cal.xml Edgar Link unprocessable
gnpx-20200930_def.xml Edgar Link unprocessable
gnpx-20200930_lab.xml Edgar Link unprocessable
gnpx-20200930_pre.xml Edgar Link unprocessable
gnpx20200930_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending